Arvinas
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
Selected company directory
This public preview is selective and unranked. Use the member workspace for the complete research maps and comparisons.
Syneron Bio
Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
Kymera Therapeutics
The 2026-10-29 announcement places KT-621 in Phase 2 for AD and asthma and reports Phase 1 healthy-volunteer results for KT-579. Sanofi is advancing KT-485 in Phase 1; Gilead is preparing a KT-200 CDK2 molecular glue IND.
Oralead Pharma
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
Triastek
T25 is an oral octreotide acetate tablet. MED&SSE produces its shell and drug-containing core; FDA IND clearance was disclosed in 2026.
Merck / MSD
LIPFENDRA is a U.S.-approved oral PCSK9 inhibitor. Its label confirms sodium caprate and approximately 1% oral bioavailability.
Bachem
Provides process development, analytical services, and GMP clinical manufacturing for cyclic peptides, stapled peptides, and peptidomimetics. Classified as a manufacturing service provider; client drugs are not treated as proprietary pipelines.
WuXi AppTec
WuXi AppTec offers Large-molecule bioanalysis, PK, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
Oral cyclic peptides · Protein degradation / PROTAC · China-listed CRO/CDMO · Bioanalysis & Biomarkers
Nurix Therapeutics
The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
Accutar Biotech
AC699 (also called AC0699 on the website) is an oral ERα chimeric degrader. Phase 1 human results and FDA Fast Track were reported in 2024.
Pharmaron
Pharmaron offers Biologics characterization, PK/TK, immunogenicity and biomarkers. This is the analytical service business of an integrated CRO/CDMO.
Protein degradation / PROTAC · China-listed CRO/CDMO · Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Crystal NAX
Offers RNA synthesis, LNP / tLNP formulation screening, analytical characterization, and early-stage manufacturing. The website describes manufacturing as GMP-like for preclinical, toxicology, and IND-enabling programs; this should not be equated with full cGMP commercial manufacturing.
Moderna
A publicly traded mRNA drug company with a disclosed platform spanning mRNA design, LNP delivery, and drug substance and drug product manufacturing.
BioNTech SE
Develops cancer and infectious disease programs using immunotherapy and mRNA platforms; COMIRNATY is a named product with regulatory validation.
Arcturus Therapeutics
Develops the LUNAR lipid delivery and STARR self-amplifying mRNA platforms. KOSTAIVE is an approved sa-mRNA COVID-19 vaccine.
TriLink BioTechnologies
Active in nucleic acid synthesis since 1996; a Maravai-owned CDMO supplying mRNA, NTPs, and CleanCap capping reagents.
Acuitas Therapeutics
Founded in 2009, this LNP delivery technology company advances nucleic acid drug delivery R&D and commercialization primarily through partners. Licensed platforms are not classified as company-owned drug candidates.
Crystal Pharmatech
The group connects candidates with clinical and commercial supply through solid-state, preformulation, oral formulation development, and manufacturing services. Formulation execution entities include CFS and Candoo.
Formulation Development & Manufacturing · Pharmaceutical solid state · MicroED structure determination
Crystal Formulation Services
CFS is a wholly owned Crystal Pharmatech subsidiary offering development, analysis, and clinical-to-commercial manufacturing of conventional and ASD oral dosage forms, with disclosed spray drying and hot-melt extrusion capabilities.
Candoo Pharmatech
This Canadian formulation provider uses QbD approaches for oral dosage form development and manufacturing process design, including immediate-release, controlled-release, bilayer, orally disintegrating, and sublingual products.
Catalent
Offers early development of small-molecule oral and injectable products. Its biologics business provides formulation, stability, and compatibility development for vials, prefilled syringes, and cartridges.
Lonza
Lonza offers Biologics analytical development, characterization and GMP testing. This is the analytical service business of an integrated CRO/CDMO.
Formulation Development & Manufacturing · Biologics Characterization & CMC Analytics
Evonik Industries / Health Care
The Health Care business offers drug delivery and CDMO services for complex oral and injectable medicines, including functional polymers, solubility enhancement for poorly soluble drugs, and LNP formulation capabilities.
Triclinic Labs
A U.S. solid-state R&D and analytical CRO offering solid-form screening, structural characterization, and intellectual-property-related studies.
Pharmaceutical solid state · MicroED structure determination
Veranova
Pharmorphix solid-state and particle engineering services are now part of Veranova, spanning screening, crystallization development, and analytical support.
Ardena
A European CDMO offering polymorph, salt, cocrystal, and amorphous-form screening and crystallization development.
Solvias
Solvias offers Biologics characterization, impurities, potency and CMC quality testing. Services should be matched to the intended study and assay requirements.
Pharmaceutical solid state · Biologics Characterization & CMC Analytics
Almac Group / Sciences
Almac Sciences' physical sciences services cover polymorph, salt, and cocrystal screening, crystallization development, and preformulation.
ELDICO Scientific
Sells ED-1 instruments and operates the ED-CRO sample submission structure determination service. The commercial service has been separately confirmed for this record.
ReadCrystal Biotechnology
Offers MicroED structure services for drugs, PROTACs, natural products, and small protein crystals.
Shuimu Biosciences
Explicitly offers small-molecule MicroED and presents protein and peptide MicroED examples, separately from SPA services.
SPERA PHARMA
A Japanese CMC CRO explicitly offering contract 3D ED / MicroED testing for fine crystalline powders, mixtures, salts, cocrystals, and tablets.
Asymchem
Building on small-molecule CDMO, the company provides research and manufacturing for peptides, oligonucleotides, antibodies, conjugates, and drug products.
Porton Pharma Solutions
Provides CDMO services for small-molecule APIs and drug products, cell and gene therapies, peptides, oligonucleotides, and conjugates.
Tigermed
Clinical CRO services include operations, regulatory affairs, pharmacovigilance, data management and statistics, SMO, and laboratories. Frontage is consolidated.
WuXi Biologics
WuXi Biologics offers Biologics structure, higher-order structure, potency, release and stability. This is the analytical service business of an integrated CRO/CDMO.
China-listed CRO/CDMO · Biologics Characterization & CMC Analytics
Crystal Bio Solutions
Crystal Bio Solutions offers Biologics mass spectrometry, CMC analytics, PK, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers · Clinical Pharmacology & Model-Informed Development
ProtaGene
ProtaGene offers Protein structure, impurities, potency and analytical comparability. Services should be matched to the intended study and assay requirements.
BioAgilytix
BioAgilytix offers Large-molecule PK, ADA, neutralizing antibodies, biomarkers and CMC analytics. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
SGS
SGS offers Protein characterization, potency, GMP release, stability and bioanalysis. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Eurofins BioPharma Services
Eurofins BioPharma Services offers Biologics characterization, GMP testing, bioanalysis and clinical biomarkers. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Intertek
Intertek offers Protein structure, higher-order structure, GMP testing, PK and immunogenicity. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Charles River Laboratories
Charles River Laboratories offers Protein characterization, biosafety, PK/TK, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
Bioanalysis & Biomarkers · Biologics Characterization & CMC Analytics
Alnylam Pharmaceuticals
Alnylam develops RNA interference medicines and presents its delivery platforms, marketed products, clinical programs, and scientific materials on its official website. This profile identifies a drug developer, rather than a contract service provider.
Ionis Pharmaceuticals
Ionis describes a portfolio of RNA- and DNA-targeted medicines, with separate pipeline, medicines, clinical-trial, and scientific-publication resources. Product-specific mechanisms and development status should be checked against dated disclosures.
Wave Life Sciences
Wave develops RNA-targeting medicines using RNA interference and RNA editing approaches. Its October 27, 2026 update describes WVE-007 as an investigational GalNAc-siRNA and WVE-006 as an investigational RNA-editing oligonucleotide. These are distinct modalities, not mRNA products.
Arrowhead Pharmaceuticals
Arrowhead develops RNAi therapeutics using its TRiM platform, which combines RNA triggers, targeting ligands, linkers, and chemical modifications. Liver and extrahepatic programs must be assessed by candidate and indication.
Silence Therapeutics
Silence Therapeutics develops siRNA medicines through its mRNAi GOLD platform. The name refers to RNA interference and gene silencing; it should not be classified as an mRNA-expression platform.
Dyne Therapeutics
Dyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
Certara
Certara offers model-informed drug-development services and biosimulation software. Its public portfolio includes Phoenix for PK/PD analysis and Simcyp for PBPK modeling, alongside development and regulatory support. Software availability does not establish a model's fitness for a particular decision.
Simulations Plus
Simulations Plus offers modeling and simulation software and consulting across discovery and development. Its public software portfolio includes GastroPlus, MonolixSuite, and QSP tools. Modeling choices and validation should follow the intended scientific question.
Allucent
Allucent describes clinical pharmacology strategy, PK/PD, pharmacometrics, modeling, and simulation. Nuventra is part of Allucent and is not counted here as a separate independent provider.
Altasciences
Altasciences offers LC-MS/MS, ligand-binding assays, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
Clinical Pharmacology & Model-Informed Development · Bioanalysis & Biomarkers
ICON plc
ICON lists population PK, PK/PD, exposure-response modeling, trial simulation, first-in-human dose prediction, and formulation-related IVIVC. These are service disclosures, not independent evidence of success for an individual project.
Aanastra
Aanastra discloses PEP-CAR, an anti-CD19 in vivo CAR-T strategy combining engineered RNA and targeting peptides for cancer and autoimmune disease. The public website does not establish a registered clinical program or validated patient outcomes.
AAVivo
AAVivo lists CD19 AVO-100, BCMA AVO-101, and dual BCMA/CD19 AVO-102 using T-cell-targeted AAV. The disclosed activities include vector production and construct optimization, not verified clinical dosing. AVO-103 is a TCR program and is kept separate from CAR-T.
Aera Therapeutics
AERA-109 is a targeted-LNP in vivo CAR-T candidate for B-cell-mediated autoimmune diseases, supported by mouse and nonhuman-primate studies. The pipeline projects clinical entry in the second half of 2026; a projected date is not proof that dosing has begun.
Alaya.bio
Alaya is a preclinical in vivo CAR-T developer. Its disclosed polymeric nanoparticle platform encapsulates lentiviral CAR vectors for targeted T-cell transduction; this is a hybrid polymer/viral approach, not simply a nonviral polymer delivery system.
AllerGene AI Therapeutics
AllerGene proposes in vivo-delivered mRNA CAR-T to target mast cells in allergic disease. Its website establishes research intent, but does not establish a named clinical candidate, patient dosing, or validated allergy outcomes. It is distinct from Allogene Therapeutics.
AlphaNa Bioscience
AlphaNa identifies AFN50 as an mRNA-based in vivo CAR-T program for autoimmune disease currently evaluated in IITs. The disclosed program is classified as investigator-initiated research; unrelated RNA programs and inconsistent codes elsewhere on the website are not used to infer additional CAR-T assets.
Frontage Laboratories
Frontage Laboratories offers Analytical development, GMP release, bioanalysis and biomarkers. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Intellia Therapeutics
Intellia presents CRISPR gene-editing science, clinical programs, and scientific publications on its official website. Its gene-editing work belongs in this broader in vivo engineering field; it should not be labeled as equivalent to in vivo CAR-T.
Beam Therapeutics
Beam develops investigational precision genetic medicines using base editing. Its website describes a delivery strategy spanning electroporation and nonviral and viral approaches. Those routes include different applications; the platform label alone does not establish in vivo efficacy.
Capstan Therapeutics / AbbVie
AbbVie completed its Capstan acquisition in August 2025. CPTX2309 uses targeted LNP in vivo CAR-T technology; the sponsor lists NCT06917742 as a recruiting Phase 1 study in healthy volunteers, rheumatoid arthritis, and SLE. Registration does not establish efficacy.
Labcorp
Labcorp offers Bioanalytical testing and biomarker quantitation. Services should be matched to the intended study and assay requirements.
Resolian
Resolian offers Bioanalysis, DMPK and biomarker testing. Services should be matched to the intended study and assay requirements.
Parexel
Parexel describes clinical pharmacology, population PK, PK/PD, exposure-response, PBPK, dose justification, and noncompartmental analysis. Model assumptions, datasets, and intended regulatory use require project-specific review.
Tessera Therapeutics
Tessera develops Gene Writing and RNA delivery technologies for genomic changes and targeted in vivo applications. Its November 2026 ASH announcement concerns preclinical studies, including CAR-T generation in nonhuman primates.
Tune Therapeutics
Tune develops TEMPO epigenetic regulation to activate or silence gene expression without cutting or changing the DNA sequence. Epigenetic modulation should be distinguished from sequence editing and permanent DNA insertion.
Sana Biotechnology
Sana develops CD8-targeted fusosome in vivo CAR-T, including SG293 and BCMA-directed SG227. Its August 2026 update describes SG293 clinical-start preparations and surrogate nonhuman-primate data, with SG227 clinical entry projected as early as 2027. Human dosing was not verified in this review.
Precision BioSciences
Precision BioSciences develops ARCUS-based in vivo editing for gene elimination, excision, and insertion. Delivery and evidence differ by program; the company describes AAV delivery for its DMD gene-excision approach.
Umoja Biopharma
VivoVec uses engineered lentiviral vectors for in vivo CAR-T. The disclosed pipeline includes CD22 UB-VV400/410 and BCMA×GPRC5D UB-VV500. IASO retains Greater China rights to the partnered CD22 programs; UB-VV111 is partnered with AbbVie. Trial registration and IND clearance do not establish efficacy.
EsoBiotec / AstraZeneca
AstraZeneca completed its acquisition in May 2025. ENaBL is a targeted lentiviral platform; anti-BCMA ESO-T01 has a published Phase 1 study in multiple myeloma. The small, uncontrolled study provides preliminary evidence, not established benefit.
Kelonia Therapeutics / Lilly
KLN-1010 is a BCMA-directed in vivo CAR-T candidate in Phase 1 for multiple myeloma, using the lentiviral iGPS platform. Lilly confirmed completion of the Kelonia acquisition in its Q2 2026 results. Early clinical findings remain investigational.
Orna Therapeutics / Lilly
Orna develops circular RNA in vivo cell therapies, including CD19-directed ORN-252 for B-cell-driven autoimmune diseases. Lilly completed the acquisition in 2026; its Q3 filing identifies ORN-252 as Phase 1 at acquisition. ReNAgade was acquired by Orna in 2024 and is not counted separately.
Interius BioTherapeutics / Kite-Gilead
Interius develops targeted lentiviral in vivo CAR therapies. Its clinical lead INT2104 targets CD20 and engineers T and NK cells. Gilead’s annual filing confirms that the acquisition closed in October 2025; Interius is a wholly owned subsidiary.
Orbital Therapeutics / BMS
BMS completed its acquisition in December 2025, obtaining OTX-201, a preclinical RNA-based in vivo CAR-T program for autoimmune disease. The filing establishes ownership and the disclosed development stage; it does not report human efficacy.
Sail Biomedicines
Sail combines eRNA with targeted nanoparticles for in vivo CAR-T in immune-mediated diseases. Its July 2026 Johnson & Johnson collaboration includes an option to acquire Sail, not a completed acquisition. A named clinical CAR-T candidate is not established by this announcement.
Strand Therapeutics
The pipeline identifies STX-005 as a circular mRNA circuit for in vivo CAR-T in autoimmune disease and blood cancers. Clinical findings from the separate IL-12 programs STX-001/003 must not be attributed to STX-005; current CAR-T clinical initiation was not verified.
Azalea Therapeutics
Azalea develops enveloped delivery vehicles (EDVs) for targeted in vivo T-cell genome engineering. Its disclosed preclinical approach includes precise TRAC-locus CAR insertion. This combines delivery and site-specific integration; human therapeutic benefit has not been established.
Ensoma
Ensoma disclosed mouse proof of concept for in vivo HSC engineering that generates CAR-bearing macrophage, NK, and T-cell lineages. This is an HSC-derived, multi-lineage approach, distinct from directly transducing mature T cells. CAR-T human efficacy is not established.
NanoCell Therapeutics
NanoCell’s NanoCAR approach uses targeted LNPs to generate CAR-T cells in vivo. Its animal proof-of-concept disclosure describes nonviral DNA delivery; this should not be classified as a transient mRNA-only platform. Clinical efficacy remains unestablished.
Kernal Biologics
Kernal combines T-cell-targeted LNP delivery with selective mRNA translation for in vivo CAR-T. Its ASGCT 2026 announcement concerns preclinical programming studies. An ARPA-H award supports development; it is research funding, not clinical validation or a venture financing round.
EXUMA Biotech
EXUMA’s GCAR platform combines CD3-targeted lentiviral delivery with FITNESS DRIVER for in vivo CAR engineering. Its separate rPOC SC platform incubates PBMCs with vector outside the body and should not be described as fully in vivo manufacturing. Current GCAR clinical stage was not verified.
Tempest Therapeutics
TPST-4003 combines CD7-targeted mRNA/LNP delivery with a CD19/BCMA CAR; first IIT dosing was projected for Q4 2026, not verified as completed. Tempest separately obtained an option to license Senlang’s clinical lentiviral platform. TPST-2003 clinical results concern ex vivo CAR-T.
Hebei Senlang Biotechnology
Senlang’s CD7-targeted lentiviral in vivo CAR-T portfolio includes a BCMA/GPRC5D candidate in Phase 1 dose escalation for relapsed/refractory myeloma. Partner Tempest disclosed an exclusive option in September 2026; an option is not an exercised license or acquisition.
CREATE Medicines
CREATE, formerly Myeloid Therapeutics, disclosed preclinical in vivo CAR-T/CAR-NK and all-RNA RetroT work at AACR 2026. Clinical MT-302 is a myeloid-cell program, not evidence that its CAR-T programs have reached the same stage. The former name is retained as an alias.
Vyriad
Vyriad develops targeted viral genetic medicines and oncolytic therapies. Its BCMA-directed in vivo CAR-T candidate VV169 uses a retargeted lentiviral vector to engineer T cells inside the body. On September 10, 2026, the company announced that its Phase 1 study in relapsed/refractory multiple myeloma was open for enrollment at Mayo Clinic following FDA IND clearance. Patient dosing and clinical benefit were not established in that announcement.
CPTx
CPTx develops single-stranded DNA payloads with nonviral LNP delivery for in vivo CAR-T. The company reports small-animal validation; durability, redosing, and immune-silence statements remain company claims. CPTx is a distinct company from Capstan and the CPTX2309 drug code.
Legend Biotech
LB2501 is a CD19/CD20 in vivo CAR-T candidate using the TaVec lentiviral platform, with an ongoing China Phase 1 study (NCT07002112). Its October 2026 U.S. IND clearance supports a planned Phase 1/2 study. Neither IND clearance nor early responses constitute approval.
IASO Biotherapeutics
IASO reported first-in-human Phase 1 data for BCMA-directed IASO206 in relapsed/refractory myeloma at IMS 2026. It also partners with Umoja on CD22 programs with territorial rights. IASO206 and Umoja’s CD22 UB-VV400 are different programs.
Immorna
Immorna reports clinical investigation of JCXH-213, an RNA-based in vivo CAR-T candidate, in autoimmune diseases including ITP and systemic sclerosis. These are company-reported early findings, not proof of comparative efficacy; separate vaccine stages do not establish this program’s stage.
GRIT Biotechnology
GRIT disclosed T-cell-targeted mRNA/LNP GT801 and a separate lentiviral direction. GT801 is also developed through spinout Vivacta Bio; the two company profiles describe a shared program lineage, not two independent drugs. GRIT’s TIL clinical stages are separate.
Genocury Biotech
Genocury’s September 2025 announcement reports an investigator-initiated study of CD19-directed in vivo CAR-T in B-cell lymphoma. A reported individual response is preliminary and does not establish durability or comparative benefit. Current enrollment and formal regulatory trial status need confirmation.
MagicRNA Biotechnology
HN2301 delivers CD19 CAR mRNA using engineered T-cell-targeted LNPs. MagicRNA reports first-in-human SLE findings published in the New England Journal of Medicine. The older English homepage’s IND-enabling description is not used to override the later human-study disclosure.
Starna Therapeutics
Starna’s pipeline includes STR-P004 and STR-P005 in vivo CAR-T programs for autoimmune disease. An ASCO abstract describes CD19 CAR mRNA in CD8-targeted LNPs and exploratory patient dosing for STR-P004. These early findings do not establish efficacy or the stage of STR-P005.
Simnova Biotherapeutics
Simnova holds Greater China development and commercialization rights for partnered Orna in vivo cell therapies. The January 2025 expansion adds BCMA to the circular RNA partnership. Territorial participation is retained without counting the partnered programs as unrelated inventions; current clinical stage was not verified.
Immunofoco
Immunofoco’s iMagic platform uses a fusogen and T-cell-targeting modules for in vivo CAR-T. It identifies CD19 IMV101 in IITs, alongside BCMA IMV102 and CLDN18.2 IMV103. Phase 3 IMC002 is an ex vivo program and does not establish in vivo Phase 3 development.
Everest Medicines
EVM18 delivers CD19 CAR mRNA in targeted LNPs. Everest’s 2026 interim results report IIT initiation in autoimmune disease and global IND preparation. EVM14 and EVM16 are cancer vaccines, not its in vivo CAR-T lead.
Oricell Therapeutics
Oricell explicitly lists OriV508, a CD19/BCMA in vivo CAR-T program, as IIT ongoing, and OriV118 targeting GPRC5D/BCMA. The pipeline does not establish the delivery platform or OriV118’s current stage. Its ex vivo OriCAR-017 data must be kept separate.
Vivacta Bio
Vivacta is a GRIT in vivo CAR-T platform spinout developing CD19 mRNA/tLNP candidate GT801. A first-in-human study is registered as NCT07205315. Its October 2026 U.S. orphan designation for AIHA is not approval or proof of efficacy; GT801 is shared with the GRIT profile.
Byterna Therapeutics
BR101 is a BCMA/CD19 circular mRNA in vivo CAR-T program in a registered IIT for relapsed/refractory myeloma (NCT07537049). Autoimmune development and BR102/BR103 are separately described as preclinical; their stages should not be inferred from BR101.
RiboX Therapeutics
RXIM002 uses targeted LNPs carrying CD19 CAR circular RNA. The August 2026 update reports ongoing China IIT follow-up and FDA IND clearance for autoimmune cytopenias. It also discloses a fatal serious adverse event in a participant with systemic sclerosis; causality should not be inferred.
Stylus Medicine
Stylus combines engineered recombinases with cell-targeted LNP delivery to create durable in vivo CAR-T through sequence-specific insertion. Its platform disclosure establishes preclinical research intent and mechanism, not patient benefit or demonstrated clinical safety.
GenVivo
GenVivo identifies GEN-310 as an in vivo CAR-T/NK program for B-cell malignancies. Its October 2025 corporate presentation classifies GEN-310 as preclinical. Clinical work on separate immunocytokine vectors should not be used to upgrade this CAR program.
Cellinfinity BIO
Manufacturing partner uBriGene identifies Cellinfinity’s CIB-301 and CIB-350 as in vivo CAR-T programs for hematologic and solid tumors, supported by lentiviral vector manufacturing. The March 2026 announcement does not establish a registered clinical phase or human efficacy.
Jenthera Therapeutics
Jenthera discloses an in vivo autologous CAR-T reprogramming program in B-cell lymphoma using targeted ribonucleoprotein genome editing and homology-directed insertion. Website tumor-eradication statements do not establish human efficacy.
ModeX Therapeutics / OPKO
ModeX, an OPKO company, lists MDX3001 as in vivo CAR-T for cancer and autoimmunity. Its platform conjugates CD3×CD28 antibodies to LNPs carrying CAR mRNA. Human dosing and the program’s precise current stage were not established by the accessible pipeline text.
Thesian Bio
Thesian’s ARIANE platform uses in vivo engineering to generate CAR-T and CAR-macrophages for oncology and autoimmune disease. The company describes lentiviral engineering expertise and a dual-lineage approach. A named clinical-stage candidate and patient efficacy were not verified.
GigaMune
GigaMune develops diverse viral pseudotypes for repeat-dose in vivo CAR-T delivery and shows anti-CD19 mouse proof of concept. Proposed sequential dosing and immune evasion are platform hypotheses; human redosing safety and efficacy have not been established.
YolTech Therapeutics
YolTech explicitly lists YOLT-401 for autoimmune disease as an in vivo CAR-T program with an undisclosed target. Its clinical gene-editing programs are separate; their stages and delivery details are not automatically assigned to YOLT-401.
Immugenia
Immugenia discloses lentiviral in vivo CAR delivery to T/NK cells and HSCs, with promoter-restricted expression in T/NK lineages. HSC-derived replenishment differs from direct mature-T-cell engineering. The public disclosure does not establish a current CAR-T clinical phase.
Hemogenyx Pharmaceuticals
An October 2026 company announcement describes an in vitro feasibility study combining FLT3 CAR mRNA with Nitto’s cell-targeted LNPs. This is an early in vivo CAR-T development effort, not human in vivo treatment. Clinical HG-CT-1 is a separate ex vivo product.
Nona Biosciences
Nona supplies antibody discovery and CAR screening for Umoja’s in vivo CAR-T collaboration. The November 2025 agreement assigns subsequent product development and commercialization to Umoja. Nona is labeled an enabling partner, not a separately confirmed clinical CAR-T developer.
uBriGene Biosciences
uBriGene provides lentiviral process development, GMP manufacturing, and regulatory support for Cellinfinity’s in vivo CAR-T programs. Its manufacturing partnership establishes an enabling role; it does not establish ownership of the therapeutic candidates.
Axelyf
Axelyf identifies AX-004 as its proprietary in vivo CAR-T candidate for solid tumors using AXL LNP delivery. Disclosed support is from mouse and non-human-primate studies; human dosing or clinical efficacy is not inferred.
Mote Therapeutics
Founded in 2023 and headquartered in Lexington, Mote was created by Fapon Group and Alex Wesselhoeft. Its mobilize platform enables targeted LNP/circRNA delivery. Its BIO 2026 presentation identifies a preclinical CD19/BCMA in vivo CAR-T lead; a projected November IIT is not proof of dosing.
Mana.bio
Mana.bio applies machine learning to LNP design and disclosed a 2026 ASGCT presentation on progress toward in vivo CAR-T. The accessible material supports delivery-platform research; a named therapeutic candidate, clinical initiation, and patient efficacy were not verified.
Pregene Biopharma
The ESO-T01 Phase 1 publication includes a Pregene-affiliated coauthor alongside EsoBiotec. This establishes participation in the published work, not independent ownership of ESO-T01 or a separate verified in vivo CAR-T pipeline. Commercial rights require further confirmation.
Velvet Therapeutics
Velvet discloses amino-acid nanoparticles and minicircle DNA for in vivo CAR delivery to multiple immune-cell types. The accessible primary page does not specify a T-cell program or clinical stage; it is retained as an adjacent CAR platform rather than counted as a confirmed CAR-T developer.
Singular Immune
Singular’s iCAR is a recombinant fusion-protein approach to modifying T or NK cells in vivo. It is kept separate from gene-encoded CAR-T because protein-based receptor installation has a different mechanism. The website does not establish human efficacy.
ImmunoVec
ImmunoVec develops programmable DNA with cell-type-specific transcriptional control; the accessible primary disclosure highlights NK cells. It is tracked as adjacent in vivo immune engineering, without assuming that CAR-NK results establish a CAR-T program or clinical stage.
Liberate Bio
Liberate’s RAPTOR delivery platform supports initial in vivo CAR-macrophage programs through monocyte/macrophage reprogramming. CAR-M is a neighboring modality, not CAR-T; these programs are not included in the confirmed CAR-T developer count.
ImmTune Therapies
ImmTune discloses delivery vectors for in-body cell and gene therapy. Its accessible updates are old and do not establish a current named CAR-T program or clinical status. It remains a platform watchlist entry, outside the confirmed CAR-T developer count.
Tidal Therapeutics / Sanofi
Sanofi acquired Tidal in April 2021 for its nanoparticle mRNA platform for in vivo immune-cell reprogramming, including CAR-T applications. This is a historical acquired-platform record; the original preclinical description is not a verified current program stage or an independent active biotech.
Alcami
Alcami offers Biologics analytical development, validation, stability and GMP release. This is the analytical service business of an integrated CRO/CDMO.
Pace Life Sciences
Pace Life Sciences offers Biologics analytical testing, potency and GMP quality control. This is the analytical service business of an integrated CRO/CDMO.
BioPharmaSpec
BioPharmaSpec offers Protein sequencing, higher-order structure, glycans and comparability. Services should be matched to the intended study and assay requirements.
Alphalyse
Alphalyse offers Mass spectrometry, protein identification and host-cell protein analysis. Services should be matched to the intended study and assay requirements.
Coriolis Pharma
Coriolis Pharma offers Biophysical characterization, formulation and stability of biologics. Services should be matched to the intended study and assay requirements.
LEUKOCARE
LEUKOCARE offers Biologics formulation, stability and particle characterization. Services should be matched to the intended study and assay requirements.
RSSL
Reading Scientific Services (RSSL) offers Biologics structure, glycans, impurities, GMP release and stability. Services should be matched to the intended study and assay requirements.
Biofidus
Biofidus offers Protein structure, mass spectrometry, glycans and biophysical characterization. Services should be matched to the intended study and assay requirements.
NUVISAN
NUVISAN offers Large-molecule QC testing, bioanalysis and clinical biomarkers. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Selvita
Selvita offers Biologics characterization, analytical development and quality control. Services should be matched to the intended study and assay requirements.
Emery Pharma
Emery Pharma offers Biologics mass spectrometry, NMR, structural characterization and impurities. Services should be matched to the intended study and assay requirements.
Avance Biosciences
Avance Biosciences offers Biologics and gene-therapy analytical testing, potency and molecular assays. Services should be matched to the intended study and assay requirements.
Texcell
Texcell offers Biosafety, cell-bank characterization and bioassays. Services should be matched to the intended study and assay requirements.
Clean Cells
Clean Cells offers Biologics potency, biosafety and cell-bank characterization. This is the analytical service business of an integrated CRO/CDMO.
Merck BioReliance
Merck BioReliance offers Biologics biosafety, cell-bank characterization and GMP testing. Services should be matched to the intended study and assay requirements.
KABS Pharmaceutical Services
KABS Pharmaceutical Services offers Analytical development, validation and quality control for biopharmaceuticals. This is the analytical service business of an integrated CRO/CDMO.
Custom Biologics
Custom Biologics offers Biologics potency, functional assays, PK and immunogenicity. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Rapid Novor
Rapid Novor offers Antibody sequencing, mass spectrometry and characterization. Services should be matched to the intended study and assay requirements.
BIOVECTRA
BIOVECTRA offers Biologics analytical development, characterization and GMP testing. This is the analytical service business of an integrated CRO/CDMO.
Biodextris
Biodextris offers Vaccine and biologics analytical development, validation and quality testing. This is the analytical service business of an integrated CRO/CDMO.
UP Pharma
军科正源 (UP Pharma) offers Protein characterization, PK, ADA, neutralizing antibodies and biomarkers. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Biotree
百趣生物 (Biotree) offers Protein characterization, developability and multiomics biomarkers. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Yaohai Bio-Pharma
耀海生物 (Yaohai Bio-Pharma) offers Recombinant proteins, nanobodies and nucleic-acid characterization and QC. This is the analytical service business of an integrated CRO/CDMO.
BioDlink
东曜药业 (BioDlink) offers Antibody and ADC characterization, higher-order structure and comparability. This is the analytical service business of an integrated CRO/CDMO.
MabPlex
迈百瑞 (MabPlex) offers Antibody and ADC structure, potency, impurities and CMC analytics. This is the analytical service business of an integrated CRO/CDMO.
Chime Biologics
鼎康生物 (Chime Biologics) offers Biologics analytical development, characterization, release and stability. This is the analytical service business of an integrated CRO/CDMO.
ProBio
ProBio offers Antibody and gene-therapy characterization, bioassays and quality control. This is the analytical service business of an integrated CRO/CDMO.
Samsung Biologics
Samsung Biologics offers Biologics identity, purity, potency, release and stability testing. This is the analytical service business of an integrated CRO/CDMO.
LOTTE Biologics
LOTTE Biologics offers Biologics method transfer, potency, release and stability testing. This is the analytical service business of an integrated CRO/CDMO.
BINEX
BINEX offers Biologics analytical development, validation and protein characterization. This is the analytical service business of an integrated CRO/CDMO.
Prestige Biologics
Prestige Biologics offers Biologics analytical testing and analytical development within CDMO services. This is the analytical service business of an integrated CRO/CDMO.
AGC Biologics
AGC Biologics offers Protein and cell/gene-therapy analytical development and quality testing. This is the analytical service business of an integrated CRO/CDMO.
KBI Biopharma
KBI Biopharma offers Biologics structure, biophysical characterization, potency and analytics. This is the analytical service business of an integrated CRO/CDMO.
Abzena
Abzena offers Antibody and bioconjugate characterization and analytical development. This is the analytical service business of an integrated CRO/CDMO.
Curia
Curia offers Biologics analytical testing, bioassays and stability. This is the analytical service business of an integrated CRO/CDMO.
FUJIFILM Biotechnologies
FUJIFILM Biotechnologies offers Biologics biochemical and biophysical characterization, potency and GMP testing. This is the analytical service business of an integrated CRO/CDMO.
Northway Biotech
Northway Biotech offers Biologics analytical development, characterization and quality control. This is the analytical service business of an integrated CRO/CDMO.
Aragen Life Sciences
Aragen Life Sciences offers Protein characterization, analytical development and clinical bioanalysis. This is the analytical service business of an integrated CRO/CDMO.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Syngene International
Syngene International offers Biologics characterization, regulated bioanalysis and clinical biomarkers. This is the analytical service business of an integrated CRO/CDMO.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
VelaLabs
VelaLabs offers Biologics characterization, GMP QC, potency and clinical bioanalysis. Services should be matched to the intended study and assay requirements.
Biologics Characterization & CMC Analytics · Bioanalysis & Biomarkers
Medicilon
Medicilon offers DMPK and preclinical bioanalysis. Services should be matched to the intended study and assay requirements.
Sannova Analytical
Sannova Analytical offers Bioanalytical development and preclinical/clinical sample analysis. Services should be matched to the intended study and assay requirements.
CellCarta
CellCarta offers Flow cytometry, histopathology, genomics and protein biomarkers. Services should be matched to the intended study and assay requirements.
Anapharm
Anapharm offers Small- and large-molecule bioanalysis, PK and immunogenicity. Services should be matched to the intended study and assay requirements.
AGADA Biosciences
AGADA Biosciences offers Rare-disease biomarkers, muscle-biopsy analysis and bioassays. Services should be matched to the intended study and assay requirements.
KCAS Bio
KCAS Bio offers PK, immunogenicity, flow cytometry and biomarker testing. Services should be matched to the intended study and assay requirements.
QPS
QPS offers Small- and large-molecule bioanalysis, immunogenicity and biomarkers. Services should be matched to the intended study and assay requirements.
Celerion
Celerion offers Clinical PK, mass spectrometry, immunoassays and biomarkers. Services should be matched to the intended study and assay requirements.
PPD Laboratory Services
PPD Laboratory Services offers Bioanalysis, immunogenicity, central laboratory and biomarker services. Services should be matched to the intended study and assay requirements.
Precision for Medicine
Precision for Medicine offers Large-molecule bioanalysis and translational biomarkers. Services should be matched to the intended study and assay requirements.
Cerba Research
Cerba Research offers PK, immunogenicity, flow cytometry and clinical biomarkers. Services should be matched to the intended study and assay requirements.
Synexa Life Sciences
Synexa Life Sciences offers Complex biomarkers, immunoassays and large/small-molecule bioanalysis. Services should be matched to the intended study and assay requirements.
Immunologix Laboratories
Immunologix Laboratories offers Immunogenicity, neutralizing antibodies, PK and biomarkers. Services should be matched to the intended study and assay requirements.
IQVIA Laboratories (including legacy Nexelis)
IQVIA Laboratories（含原Nexelis） offers PK, immunogenicity, vaccine assays and biomarkers; includes legacy Nexelis. Services should be matched to the intended study and assay requirements.
Inotiv
Inotiv offers DMPK, clinical bioanalysis and biomarkers. Services should be matched to the intended study and assay requirements.
PharmaLegacy
PharmaLegacy offers Preclinical biomarkers, flow cytometry and immunoassays. Services should be matched to the intended study and assay requirements.
InnoStar
益诺思 (InnoStar) offers PK/TK, clinical bioanalysis and translational biomarkers. Services should be matched to the intended study and assay requirements.
JOINN Laboratories
昭衍新药 (JOINN Laboratories) offers PK, immunogenicity, molecular assays and bioanalysis. Services should be matched to the intended study and assay requirements.
R&G PharmaStudies
诺思格 (R&G PharmaStudies) offers Bioanalysis and clinical pharmacology. Services should be matched to the intended study and assay requirements.
Sun-Novo
阳光诺和 (Sun-Novo) offers Clinical bioanalysis and bioequivalence services. Services should be matched to the intended study and assay requirements.
ADICON
艾迪康 (ADICON) offers Clinical-trial central laboratory, molecular pathology and biomarkers. Services should be matched to the intended study and assay requirements.
KingMed
金域医学 (KingMed) offers Clinical-trial central laboratory and biomarker testing. Services should be matched to the intended study and assay requirements.
SCL Healthcare
SCL Healthcare offers Clinical-trial laboratory, mass-spectrometry PK and biomarker development. Services should be matched to the intended study and assay requirements.
BioInfra
BioInfra offers Bioanalytical sample testing and bioequivalence studies. Services should be matched to the intended study and assay requirements.
Biotoxtech
Biotoxtech offers Preclinical bioanalysis and PK/TK, including Keyfron Bio services. Services should be matched to the intended study and assay requirements.
HLB bioStep
HLB bioStep offers Preclinical PK/TK, mass spectrometry, flow cytometry and biomarkers. Services should be matched to the intended study and assay requirements.
Novotech
Novotech offers Large-molecule PK, ADA, neutralizing antibodies and clinical laboratory testing. Services should be matched to the intended study and assay requirements.
Lablytica
Lablytica offers Regulated small- and large-molecule bioanalysis and biomarkers. Services should be matched to the intended study and assay requirements.
Admescope
Admescope offers Non-GLP quantitative bioanalysis, DMPK and biomarker studies. Services should be matched to the intended study and assay requirements.
Chimera Biotec
Chimera Biotec offers Ultrasensitive immunoassays, large-molecule bioanalysis and biomarkers. Services should be matched to the intended study and assay requirements.
Oxford BioDynamics
Oxford BioDynamics offers Epigenetic biomarker discovery and 3D-genomics research services. Services should be matched to the intended study and assay requirements.
Biognosys
Biognosys offers Mass-spectrometry proteomics, metabolomics and biomarker research. Services should be matched to the intended study and assay requirements.
Metabolon
Metabolon offers Metabolomics and biomarker discovery and analysis. Services should be matched to the intended study and assay requirements.
Allumiqs
Allumiqs offers Mass-spectrometry proteomics, multiomics and biomarker discovery. Services should be matched to the intended study and assay requirements.
Syneos Health
Syneos Health offers Small- and large-molecule PK, immunogenicity and biomarker testing. Services should be matched to the intended study and assay requirements.